Meeting
2020 Genitourinary Cancers Symposium
Adding mitomycin to Bacillus Calmette-Guérin as adjuvant intravesical therapy for high-risk, nonmuscle-invasive urothelial bladder cancer (BCGMM; ANZUP 1301).
Authors
Elizabeth Chien Hern Liow
Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Camperdown, NSW, Australia
Elizabeth Chien Hern Liow , Dickon Hayne , Martin R. Stockler , Andrew James Martin , Shomik Sengupta , Paul Anderson , Kate Ford , Mark Frydenberg , Margot Gorzeman , Will Green , Jeremy Grummet , Cynthia Hawks , Laurence Eliot Miles Krieger , Joseph Ischia , Steve McCombie , Manish Patel , Ian D. Davis
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers
Track
Urothelial Carcinoma,Adrenal Cancer,Penile Cancer,Prostate Cancer - Advanced,Prostate Cancer - Localized,Testicular Cancer,Urethral Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT02948543
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr TPS602)
Abstract #
TPS602
Poster Bd #
N20
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Adding mitomycin (MM) to bacillus Calmette-Guérin (BCG) as adjuvant intravesical therapy for high-risk, non–muscle-invasive urothelial bladder cancer (NMIBC): BCGMM; ANZUP 1301.
First Author: Dickon Hayne
Poster
2024 ASCO Genitourinary Cancers Symposium
Punch: Preliminary results from a phase II study of intra‑arterial chemotherapy (IAC) combined with tislelizumab and bacillus Calmette-Guerin (BCG) in high-risk non-muscle-invasive bladder cancer (HR NMIBC).
First Author: Zongren Wang
Poster
2024 ASCO Genitourinary Cancers Symposium
Phase 3 KEYNOTE-676 cohort A: Bacillus Calmette-Guérin (BCG) with or without pembrolizumab for high-risk (HR) non–muscle-invasive bladder cancer (NMIBC) that persists/recurs after BCG induction.
First Author: Neal D. Shore
Poster
2024 ASCO Genitourinary Cancers Symposium
Reasons for refusal of or ineligibility for radical cystectomy (RC) in patients (Pts) with bacillus Calmette-Guérin (BCG)–unresponsive high-risk non–muscle-invasive bladder cancer (HR NMIBC) from the SunRISe-1 study.
First Author: Joseph M Jacob